The National Agency for Food and Drug Administration and Control has addressed reports suggesting that it hindered the importation of essential antileprosy medications into Nigeria. In a statement, the agency clarified that it upholds strict quality control measures to protect public health.
NAFDAC highlighted its Clean Report of Inspection and Analysis Scheme, which ensures that medicines from high-risk countries like India and China meet global quality standards before entering Nigeria. One crucial aspect of this scheme is the Certificate of Pharmaceutical Product, a globally recognized document issued by the exporting country’s regulatory authority.
The agency stated that the manufacturer of the antileprosy drugs in question did not secure the necessary COPP from Indian authorities. After a request from the World Health Organization, NAFDAC sought laboratory test results from an approved CRIA laboratory in India. Upon receiving satisfactory results, the agency approved the export of the medicines to Nigeria, balancing patient needs with regulatory compliance.
NAFDAC reiterated its commitment to reducing Nigeria’s dependence on imported medicines by bolstering regulatory frameworks and supporting local pharmaceutical manufacturers. The agency emphasized its dedication to ensuring the availability of safe, effective, and high-quality medicines in Nigeria.